Sarcoidosis is a systemic chronic granulomatous disease involving the lungs, eyes and skin, often affecting young adults. Although of unknown etiology, sarcoidosis has been postulated to result from an immunological response to an environmental or antigenic trigger. Sarcoidosis has been associated with infectious and inflammatory conditions; however, the development of de novo sarcoidosis following allogeneic hematopoietic cell transplantation (alloHCT) has rarely been reported. A genetic predisposition to sarcoidosis is suggested due to familial clustering of cases and the increased prevalence in some ethnic groups. Sarcoidosis has been associated with specific gene products residing in the MHC. 1, 2 Specifically, the HLA class I Ags, A1 and B8, and class II Ag, DR3, are present in higher frequencies in sarcoidosis patients. 1, 2 In addition, the class II alleles DRB1*0301 and DQB1*0201 (DQ2) are associated with acute sarcoidosis and a good prognosis, whereas DRB1*1501 and DQB1*0602 have the opposite effect. 2 We report a case of sarcoidosis following alloHCT in a patient with the A1, B8, DR3 and DQ2 haplotypes, as well as DRB1*1501 and DQB1*0602. We postulate that immune dysregulation post alloHCT may promote sarcoidosis development in patients with susceptible HLA types (A1, B8 and DR3).
A 47-year-old white woman presented with fatigue and was diagnosed with chronic myelomonocytic leukemia in 2006. Cytogenetic study revealed 47,XX, inv (9)(p11;q13) and trisomy 21. She received two cycles of decitabine with minimal response and underwent an HLA-identical alloHCT using mobilized peripheral blood from her HLA-matched sister with BU and CY conditioning 6 months after diagnosis. The HLA typing was A*0101, A*2501, B*0801, B*1801, DRB1*0301, DRB1*1501, DQB1*0201 and DQB1*0602. She received tacrolimus and mycophenolate mofetil for GvHD prophylaxis. She engrafted on day 13 post alloHCT and developed acute lower gastrointestinal GvHD requiring methylprednisolone treatment that was tapered off 4 months post-HCT. Two months later, she developed cutaneous chronic GvHD (cGvHD) with an erythematous papular rash, which was treated with topical steroids. She developed a cough along with worsening cutaneous, ocular and vaginal cGvHD. Chest computed tomography (CT) scan revealed mildly enlarged mediastinal and bilateral infrahilar lymph nodes up to 2 cm. She was treated with methylprednisolone, tacrolimus and photopheresis, which led to clinical improvement. A subsequent chest CT scan demonstrated resolution of lymphadenopathy, and the steroids and tacrolimus were tapered off within 1 year. A follow-up chest CT scan done 2 months later showed interval enlargement of mediastinal, hilar and subcarinal lymphadenopathy and ill-defined lung infiltrates. A positron emission tomography scan demonstrated extensive fludeoxyglucoseavid nodal disease. Bronchoscopy revealed normal endobronchial anatomy without lesions. Mediastinoscopy and right paratracheal lymph node biopsy demonstrated noncaseating epitheloid granulomas ( Figure 1 ) with negative acid fast bacilli and Giemsa (fungal) stains and no evidence of malignancy. Bacterial, fungal and tuberculosis cultures were negative. At the same time, she developed a 3 Â 3.5 cm indurated erythematous plaque on the left shin, which was biopsied. The pathology revealed poorly defined granulomatous inflammation in the deep dermis. Special stains were negative, as were bacterial, TB and fungal cultures. Serum angiotensin-converting enzyme (ACE) level was elevated at 97 U/L (normal, 12-68 U/L). The diagnosis of de novo sarcoidosis was made and she was started on methylprednisone 20 mg daily along with tacrolimus, mycophenolate mofetil and re-initiation of photopheresis. The skin lesion resolved within a month and the lung infiltrates and lymphadenopathy resolved within 5 months. The patient remains on low-dose steroids, tacrolimus and photopheresis for cGvHD. Of note, there is morphea in the location of the sarcoid plaque. One year later, the chest CT scan remains normal. 
com/bmt
The donor was a 37-year-old white woman who was in good health at the time of alloHCT and remains asymptomatic. She is a marathon runner. After the recipient's diagnosis of sarcoidosis, the donor was found to have a normal chest X-ray and serum ACE level.
Previous cases of sarcoidosis post alloHCT have been reported in recipients who received stem cells from siblings diagnosed with sarcoidosis, suggesting donor cell-derived sarcoidosis. [3] [4] [5] However, there are some cases where the donor had no evidence of sarcoidosis. 6 Patient characteristics of all reported cases of sarcoidosis post alloHCT are summarized in Table 1 .
Sarcoidosis is an immune-mediated disorder. PostalloHCT immune dysregulation and delayed immune reconstitution could facilitate the development of sarcoidosis. Of interest, all reported cases except one 7 developed sarcoidosis after complete donor engraftment, suggesting initiation by the donor immune system. One report, however, noted relapse of CML with BM granuloma and an increased ACE level 7 that resolved after donor lymphocyte infusion.
The major pathological features of sarcoidosis include non-caseating granulomas, organized macrophage and epithelioid aggregations encircled by lymphocytes. Granuloma formation is initiated by the interaction between CD4 þ T cells and HLA class II Ag peptide complex leading to T-cell activation, differentiation into Th1 cells, secretion of IL-2 and IFN-g, and augmented macrophage TNF-a production resulting in immune response amplification. 8 The alloHCT conditioning regimen and underlying disease damage host tissues inducing pro-inflammatory cytokines (for example, TNF-a), chemokines and costimulatory molecules on host APCs. Donor T cells proliferate and differentiate in response to activated host APCs. Activated donor T cells express IFN-g, IL-2 and TNF-a, leading to T-cell expansion and differentiation to Th1 vs Th2 subtypes. 9 Such immune dysregulation post alloHCT provides a similar immunological environment for the development of sarcoidosis.
In addition to immune dysregulation, genetic predisposition has an important role in the development of sarcoidosis. Higher frequencies of HLA class I Ags A1 and B8 and class II Ag DR3 are found in sarcoidosis patients. 1, 2 In the three case reports of post alloHCT sarcoidosis, in which HLA typing was mentioned, the same sarcoidosis-associated HLA type (A1, B8 and DR3) were cited. 3, 5, 7 Unfortunately, not all reports have mentioned the HLA typing. 4, 6 We suspect that the immune dysregulation post alloHCT promotes development of de novo sarcoidosis in a subgroup of HLA-susceptible patients. Understanding the association of these specific HLA types with sarcoidosis may further the understanding of the mechanisms of sarcoidosis. One should have an increased index of suspicion for sarcoidosis when evaluating post alloHCT patients with granulomatous disease in the lung, liver or skin, especially those patients with susceptible HLA types. 
